Gilead's $1.275 billion PepStar deal: what HCXT-2001 adds

Gilead has agreed to pay $1.275 billion in upfront cash at closing for PepStar's oral IL-23 receptor inhibitor program, led by HCXT-2001. The October 22 agreement would add a Phase 1 macrocyclic peptide to an inflammatory bowel disease (IBD) pipeline that already includes emvistegrast, a separate investigational drug with a different target.[1]

Reader offer · IQON Labs

Buy 1, Get 1 20% Off

Pick any two research compounds. Take 20% off the lower priced one.

20% OFF

Applied automatically at checkout, no code needed

Claim my 20% off →

In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.

Reporting on investigational drug development. Research reagents advertised on this page are separate from the programs discussed here.

What the $1.275 billion buys

The agreement covers worldwide rights to the program, including HCXT-2001. Gilead describes the payment as upfront cash, subject to customary adjustments and payable when the transaction closes. Closing remains subject to customary conditions, with completion expected in the fourth quarter of 2026.[1]

The transaction is a program acquisition from privately held PepStar Therapeutics. It is not an acquisition of the company itself, and the headline payment is not a total assembled from possible future milestones.[1]

Why target the IL-23 receptor?

IL-23 is an immune signaling protein. When it binds its receptor on a responsive cell, it starts a chain of signals that can sustain inflammation. Blocking that interaction is one way to interrupt the pathway. Antibodies can target IL-23 itself; a receptor-blocking peptide approaches the same signaling system from the receiving side.[5]

The distinction matters chemically. A peptide is a chain of amino acids, and a macrocyclic peptide contains a large ring in that structure. Work on another oral IL-23 receptor peptide, JNJ-77242113, showed how a chemically synthesized ring-containing molecule could bind the receptor and inhibit its signaling. Those experiments provide a rationale for the approach, not results for HCXT-2001.[5]

The first study asks what happens to the drug in the body

A publicly registered HCXT-2001 study, NCT07792928, plans to enroll 40 healthy adults aged 18 to 45 in New Zealand. It compares two tablet formulations with placebo after a single administration. The October 13 registry update still lists the study as not yet recruiting, so the planned enrollment cannot be read as 40 people already studied.[2]

Its main outcomes concern adverse events and clinical checks. Other measurements follow pharmacokinetics, meaning how drug concentrations change as the body absorbs and clears a compound. These include peak concentration, total exposure and elimination half-life, a measure of how slowly drug concentrations fall. The record assigns these assessments a Day 1 through Day 50 window.[2]

The study also plans to look for antibodies against the drug, including antibodies that could neutralize it. This combination of exposure and immune-response measurements helps explain what early development has to resolve before interpreting disease outcomes. The registration contains no posted results, and healthy-volunteer testing is not a trial of symptom improvement in people with bowel disease.[2]

Emvistegrast is the more advanced, separate program

Three days before announcing the PepStar agreement, Gilead reported positive Phase 2 findings for emvistegrast, also called GS-1427. That study, SWIFT, enrolled 238 adults with moderately to severely active ulcerative colitis. Its initial comparison randomly assigned participants to emvistegrast or placebo for 12 weeks.[3]

Emvistegrast targets an immune-system protein called alpha-4-beta-7 integrin, rather than IL-23R. Gilead has proposed studying HCXT-2001 alone or in combinations, including with emvistegrast. The proposed pairing would bring two different mechanisms into the same development plan.[1][3]

SWIFT's primary endpoint was clinical response, an improvement defined using stool frequency, rectal bleeding and an endoscopic examination of the bowel lining. Remission was a separate, stricter endpoint requiring little remaining disease activity. Response can therefore capture a partial improvement while remission asks whether disease activity has fallen to a much lower level. SWIFT tested emvistegrast on its own.[4]

Gilead's announcement described serious adverse events among emvistegrast recipients and said they were judged unrelated to the study drug. The company plans further maintenance data and a Phase 3 study of emvistegrast on its own in 2027. The combination remains a separate research proposal.[3]

Closing the deal and proving a combination are different milestones

The SWIFT registry already sets out questions beyond the induction result: remission at Week 52 and safety observation extending up to 116 weeks plus 28 days after the first dose. The longer follow-up is designed to examine outcomes after the initial response assessment. Its duration should not be mistaken for evidence that every participant has already completed that observation.[4]

HCXT-2001's healthy-volunteer study addresses an earlier set of questions: what exposure the formulations produce and what adverse effects or immune responses occur. Those findings will shape the interpretation of later patient studies. For the proposed combination, the clinically meaningful advance would be a trial showing what the pairing adds to either drug alone. Closing a transaction cannot answer that question.[2][3][4]